{"id":47625,"date":"2020-06-26T01:00:54","date_gmt":"2020-06-25T23:00:54","guid":{"rendered":"https:\/\/www.cde.ual.es\/?p=47625"},"modified":"2020-06-26T07:52:01","modified_gmt":"2020-06-26T05:52:01","slug":"global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines","status":"publish","type":"post","link":"https:\/\/www.cde.ual.es\/en\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\/","title":{"rendered":"Global regulators discuss data requirements for phase 3 trials of COVID-19 vaccines"},"content":{"rendered":"

Under the umbrella of the\u00a0International Coalition of Medicines Regulatory Authorities<\/a> (ICMRA), international regulators discussed COVID-19 vaccine development<\/strong> and the necessary evidence required for regulatory decision-making at the second regulatory workshop on COVID-19 vaccines.<\/p>\n

\"\"<\/a><\/p>\n

The meeting was jointly organised by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) on 22 June 2020.<\/p>\n

Many researchers around the world are currently working on vaccines against COVID-19 but a rapid authorisation of COVID-19 vaccines will only be possible if robust and sound scientific evidence on vaccine candidates\u2019 quality, safety and\u00a0efficacy\u00a0is generated. International convergence of data requirements is intended to encourage and accelerate the development of vaccines as a global public health good.<\/p>\n

During the workshop, global regulators focused on requirements for non-clinical and clinical data<\/strong> from early phase studies that are needed before proceeding with advanced (phase 3)\u00a0clinical trials\u00a0with COVID-19 vaccine candidates in humans. They exchanged views on key aspects, such as eligibility criteria for inclusion of diverse populations, primary endpoints and other methodological considerations related to the design of phase 3\u00a0clinical trials.<\/p>\n

The meeting built on the experience and knowledge gained from the first workshop on COVID-19 vaccine development held in March 2020, which underlined the urgency of conducting\u00a0clinical trials\u00a0with COVID-19 vaccine candidates in humans and international regulators\u2019 commitment to exchange information about the global efforts towards developing vaccines against COVID-19. The second workshop brought together 100 participants from more than 20 countries, representing 28 medicines regulatory authorities and the World Health Organization.<\/p>\n

The workshop was moderated by Dr Marco Cavaleri, Head of Biological Health Threats and Vaccines Strategy at EMA, and Dr Marion Gruber, Director of Office of Vaccines Research & Review at the US FDA. More details on the discussions and the outcomes of the meeting will be shared in the coming days.<\/p>\n

More information<\/h3>\n

Full news<\/a><\/p>\n

Global regulators discuss data requirements for phase 3 trials of COVID-19 vaccines<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Under the umbrella of the\u00a0International Coalition of Medicines Regulatory Authorities (ICMRA), international regulators discussed COVID-19 vaccine development and the necessary evidence required for regulatory decision-making at the second regulatory workshop on COVID-19 vaccines. The meeting was jointly organised by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) on 22 June […]<\/p>\n","protected":false},"author":101012,"featured_media":41824,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":"","footnotes":""},"categories":[4093,346,4094,4092],"tags":[1352,2366,1688],"class_list":{"0":"post-47625","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-diseases","8":"category-eu-news","9":"category-farmac","10":"category-health","11":"tag-covid-19","12":"tag-covid-19-2-en","13":"tag-vaccines","14":"entry"},"acf":[],"yoast_head":"\nGlobal regulators discuss data requirements for phase 3 trials of COVID-19 vaccines | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cde.ual.es\/en\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global regulators discuss data requirements for phase 3 trials of COVID-19 vaccines | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda\" \/>\n<meta property=\"og:description\" content=\"Under the umbrella of the\u00a0International Coalition of Medicines Regulatory Authorities (ICMRA), international regulators discussed COVID-19 vaccine development and the necessary evidence required for regulatory decision-making at the second regulatory workshop on COVID-19 vaccines. The meeting was jointly organised by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) on 22 June […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cde.ual.es\/en\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\/\" \/>\n<meta property=\"og:site_name\" content=\"CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/cdeuniversidadalmeria\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-25T23:00:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-06-26T05:52:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2020\/04\/close-up-view-of-person-holding-a-vaccine-4047183-2-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2017\" \/>\n\t<meta property=\"og:image:height\" content=\"2560\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"BECACDE1\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@cdeualmeria\" \/>\n<meta name=\"twitter:site\" content=\"@cdeualmeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BECACDE1\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\\\/\"},\"author\":{\"name\":\"BECACDE1\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#\\\/schema\\\/person\\\/bf2f837cf3353e2161fe1087adbd728f\"},\"headline\":\"Global regulators discuss data requirements for phase 3 trials of COVID-19 vaccines\",\"datePublished\":\"2020-06-25T23:00:54+00:00\",\"dateModified\":\"2020-06-26T05:52:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\\\/\"},\"wordCount\":323,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/close-up-view-of-person-holding-a-vaccine-4047183-2-scaled.jpg\",\"keywords\":[\"covid-19\",\"covid-19\",\"vaccines\"],\"articleSection\":[\"Diseases\",\"EU News\",\"Farmaceutical\",\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\\\/\",\"url\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\\\/\",\"name\":\"Global regulators discuss data requirements for phase 3 trials of COVID-19 vaccines | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/close-up-view-of-person-holding-a-vaccine-4047183-2-scaled.jpg\",\"datePublished\":\"2020-06-25T23:00:54+00:00\",\"dateModified\":\"2020-06-26T05:52:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/close-up-view-of-person-holding-a-vaccine-4047183-2-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/close-up-view-of-person-holding-a-vaccine-4047183-2-scaled.jpg\",\"width\":2017,\"height\":2560},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EU News\",\"item\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/category\\\/eu-news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Health\",\"item\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/category\\\/eu-news\\\/health\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Diseases\",\"item\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/category\\\/eu-news\\\/health\\\/diseases\\\/\"},{\"@type\":\"ListItem\",\"position\":5,\"name\":\"Global regulators discuss data requirements for phase 3 trials of COVID-19 vaccines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#website\",\"url\":\"https:\\\/\\\/www.cde.ual.es\\\/\",\"name\":\"CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda\",\"description\":\"Centro de Documentaci\u00f3n Europea de la Universidad de Almer\u00eda\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#organization\"},\"alternateName\":\"CDE Almer\u00eda\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cde.ual.es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#organization\",\"name\":\"Centro de Documentaci\u00f3n Europea de Almer\u00eda\",\"url\":\"https:\\\/\\\/www.cde.ual.es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/cde-logo-3.png\",\"contentUrl\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/cde-logo-3.png\",\"width\":1400,\"height\":300,\"caption\":\"Centro de Documentaci\u00f3n Europea de Almer\u00eda\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/cdeuniversidadalmeria\\\/\",\"https:\\\/\\\/x.com\\\/cdeualmeria\",\"https:\\\/\\\/www.tiktok.com\\\/@cdealmeria\",\"https:\\\/\\\/www.instagram.com\\\/cdealmeria\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/cde-almera-812b26a9\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#\\\/schema\\\/person\\\/bf2f837cf3353e2161fe1087adbd728f\",\"name\":\"BECACDE1\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g\",\"caption\":\"BECACDE1\"},\"sameAs\":[\"http:\\\/\\\/www.cdealmeria.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Global regulators discuss data requirements for phase 3 trials of COVID-19 vaccines | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cde.ual.es\/en\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\/","og_locale":"en_US","og_type":"article","og_title":"Global regulators discuss data requirements for phase 3 trials of COVID-19 vaccines | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda","og_description":"Under the umbrella of the\u00a0International Coalition of Medicines Regulatory Authorities (ICMRA), international regulators discussed COVID-19 vaccine development and the necessary evidence required for regulatory decision-making at the second regulatory workshop on COVID-19 vaccines. The meeting was jointly organised by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) on 22 June […]","og_url":"https:\/\/www.cde.ual.es\/en\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\/","og_site_name":"CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda","article_publisher":"https:\/\/www.facebook.com\/cdeuniversidadalmeria\/","article_published_time":"2020-06-25T23:00:54+00:00","article_modified_time":"2020-06-26T05:52:01+00:00","og_image":[{"width":2017,"height":2560,"url":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2020\/04\/close-up-view-of-person-holding-a-vaccine-4047183-2-scaled.jpg","type":"image\/jpeg"}],"author":"BECACDE1","twitter_card":"summary_large_image","twitter_creator":"@cdeualmeria","twitter_site":"@cdeualmeria","twitter_misc":{"Written by":"BECACDE1","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cde.ual.es\/en\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\/#article","isPartOf":{"@id":"https:\/\/www.cde.ual.es\/en\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\/"},"author":{"name":"BECACDE1","@id":"https:\/\/www.cde.ual.es\/#\/schema\/person\/bf2f837cf3353e2161fe1087adbd728f"},"headline":"Global regulators discuss data requirements for phase 3 trials of COVID-19 vaccines","datePublished":"2020-06-25T23:00:54+00:00","dateModified":"2020-06-26T05:52:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cde.ual.es\/en\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\/"},"wordCount":323,"commentCount":0,"publisher":{"@id":"https:\/\/www.cde.ual.es\/#organization"},"image":{"@id":"https:\/\/www.cde.ual.es\/en\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2020\/04\/close-up-view-of-person-holding-a-vaccine-4047183-2-scaled.jpg","keywords":["covid-19","covid-19","vaccines"],"articleSection":["Diseases","EU News","Farmaceutical","Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.cde.ual.es\/en\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.cde.ual.es\/en\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\/","url":"https:\/\/www.cde.ual.es\/en\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\/","name":"Global regulators discuss data requirements for phase 3 trials of COVID-19 vaccines | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda","isPartOf":{"@id":"https:\/\/www.cde.ual.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cde.ual.es\/en\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\/#primaryimage"},"image":{"@id":"https:\/\/www.cde.ual.es\/en\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2020\/04\/close-up-view-of-person-holding-a-vaccine-4047183-2-scaled.jpg","datePublished":"2020-06-25T23:00:54+00:00","dateModified":"2020-06-26T05:52:01+00:00","breadcrumb":{"@id":"https:\/\/www.cde.ual.es\/en\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cde.ual.es\/en\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cde.ual.es\/en\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\/#primaryimage","url":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2020\/04\/close-up-view-of-person-holding-a-vaccine-4047183-2-scaled.jpg","contentUrl":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2020\/04\/close-up-view-of-person-holding-a-vaccine-4047183-2-scaled.jpg","width":2017,"height":2560},{"@type":"BreadcrumbList","@id":"https:\/\/www.cde.ual.es\/en\/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/www.cde.ual.es\/en\/"},{"@type":"ListItem","position":2,"name":"EU News","item":"https:\/\/www.cde.ual.es\/en\/category\/eu-news\/"},{"@type":"ListItem","position":3,"name":"Health","item":"https:\/\/www.cde.ual.es\/en\/category\/eu-news\/health\/"},{"@type":"ListItem","position":4,"name":"Diseases","item":"https:\/\/www.cde.ual.es\/en\/category\/eu-news\/health\/diseases\/"},{"@type":"ListItem","position":5,"name":"Global regulators discuss data requirements for phase 3 trials of COVID-19 vaccines"}]},{"@type":"WebSite","@id":"https:\/\/www.cde.ual.es\/#website","url":"https:\/\/www.cde.ual.es\/","name":"CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda","description":"Centro de Documentaci\u00f3n Europea de la Universidad de Almer\u00eda","publisher":{"@id":"https:\/\/www.cde.ual.es\/#organization"},"alternateName":"CDE Almer\u00eda","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cde.ual.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.cde.ual.es\/#organization","name":"Centro de Documentaci\u00f3n Europea de Almer\u00eda","url":"https:\/\/www.cde.ual.es\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cde.ual.es\/#\/schema\/logo\/image\/","url":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2025\/07\/cde-logo-3.png","contentUrl":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2025\/07\/cde-logo-3.png","width":1400,"height":300,"caption":"Centro de Documentaci\u00f3n Europea de Almer\u00eda"},"image":{"@id":"https:\/\/www.cde.ual.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/cdeuniversidadalmeria\/","https:\/\/x.com\/cdeualmeria","https:\/\/www.tiktok.com\/@cdealmeria","https:\/\/www.instagram.com\/cdealmeria\/","https:\/\/www.linkedin.com\/in\/cde-almera-812b26a9\/"]},{"@type":"Person","@id":"https:\/\/www.cde.ual.es\/#\/schema\/person\/bf2f837cf3353e2161fe1087adbd728f","name":"BECACDE1","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g","caption":"BECACDE1"},"sameAs":["http:\/\/www.cdealmeria.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/posts\/47625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/users\/101012"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/comments?post=47625"}],"version-history":[{"count":0,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/posts\/47625\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/media\/41824"}],"wp:attachment":[{"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/media?parent=47625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/categories?post=47625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/tags?post=47625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}